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ABSTRACT
Niclosamide has been demonstrated with inhibitory activity on the replication of SARS-CoV in Vero E6 cells. This study
examined the pharmacokinetics and oral bioavailability of niclosamide and its two analogs, BPR1H366 and BPR1H369, in
male Sprague-Dawley rats. After a single 2-mg/kg intravenous dose, the total body clearance (CL) of niclosamide, BPR1H366
and BPR1H369 was 20.0 ± 2.9, 26.7 ± 4.4 and 39.4 ± 6.7 mL/kg/min, and the volume of distribution at steady state (VSS) was
0.9 ± 0.4, 0.3 ± 0.1 and 1.1 ± 0.2 L/kg, respectively. The half-life (t1/2) of BPR1H366 and BPR1H369 was 2.6 ± 0.3 and 3.7 ±
1.1 hr, respectively, shorter than 6.7 ± 2.0 hr of niclosamide. The AUC was 1413 ± 118, 1019 ± 203 and 750 ± 113 ng/mL × hr
for niclosamide, BPR1H366 and BPR1H369, respectively. After a single 5-mg/kg oral dose, all three compounds were rapidly
absorbed. Niclosamide showed the highest Cmax of 354 ± 152 ng/mL within 30 min after oral gavage. The oral bioavailability
of niclosamide, BPR1H366 and BPR1H369 was 10%, 12% and 15%, respectively. Our results demonstrated that the extents of
drug exposure of the three compounds were comparable in rats. The pharmacokinetic properties of the compounds in humans are
needed to be determined before their potential uses in SARS-CoV infected patients.
Key words: SARS, Coronavirus, Niclosamide, Pharmacokinetics, Bioavailability.

INTRODUCTION
Severe Acute Respiratory Syndrome (SARS) is a
respiratory illness caused by the infection of Severe Acute
Respiratory Syndrome coronavirus (SARS-CoV) (1-2) .
The major symptoms of SARS are hyperpyrexia, chilling, cough and dyspnea. This disease emerged in several
countries during the period of November 2002 to June
2003. World Health Organization (WHO) reported a total
of 8096 SARS patients that were accompanied by either
pneumonia or respiratory distress syndrome worldwide
and of these 774 patients died(3). Neither antiviral therapy nor vaccine is currently available. The outbreak of
SARS pandemic has led to the search for active antiviral
compounds to treat the disease.
Niclosamide [5-chloro-N-(2-chloro-4-nitrophenyl)-2hydroxybenzamide] is an effective anthelmintic drug for
the treatment of intestinal cestode in fections in humans
and animals in many countries for a few decades(4-5). It
is also used as a molluscicide for treating water in the
control of schistosomiasis(6-7). A previous study reported
that niclosamide exhibited a concentration-dependent
inhibitory effect on the replication of SARS-CoV in Vero
E6 cells (8). An in silico binding study used the crystal
structure of the SARS-CoV main proteinase, 3CLpro, a
key enzyme for the proteolytic processing of the replicase
* Author for correspondence. Tel: +886-37-246166 ext. 35711;
Fax: +886-37-586456; E-mail: ctchen@nhri.org.tw

polyproteins 1a and 1ab, demonstrated the binding of
niclosamide to the protein, and suggested niclosamide as a
template for designing SARS-CoV proteinase inhibitors(9).
Niclosamide is active against the SARS-CoV in the
micromolar levels as previously reported (8), it serves as
a validated drug lead from which active anti-SARS-CoV
analogs with optimal pharmacokinetic properties may be
designed. Two niclosamide analogs, BPR1H366 [5-chloro-N-(2, 4-dichloro)-2-hydroxybenzamide] and BPR1H369
[5-chloro-N-(2-chloro-4-trif luoromethyl)-2-hydroxybenzamide], were designed and synthesized as shown in
Figure 1. The purpose of this study was to determine the
pharmacokinetic parameters and the oral bioavailability of
niclosamide and its two chemical analogs in rats.

MATERIALS
I. Chemicals
Niclosamide (Lot No. 047H0703) and naproxen (Lot
No. 02230LB), as the internal standard, were purchased
from Sigma-Aldrich Corp. (St. Louis, Missouri, USA).
BPR1H366 and BPR1H369 were synthesized and provided
by H. P. Hsieh of the Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes,
Miaoli, Taiwan, ROC. The chemical purity for both
niclosamide analogs was greater than 99%. All of the
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other chemicals were of reagent grade and were obtained
commercially.
II. Animal Study
Male Sprague-Dawley rats of 330-380g were obtained
from BioLasco, Taiwan Co., Ilan, Taiwan. Animals were
surgically implanted with a jugular-vein cannula one day
before dosing and fasted for 12 hr prior to oral dosing.
The compounds were administered intravenously (i.v.) and
orally (p.o.) at a dose of 2-mg/kg and 5-mg/kg, respectively. The dosing solutions were prepared by dissolving
the compound in a mixture of dimethyl sulfoxide (DMSO)/
cremophor EL/water (3/15/82 v/v/v). The dosing solutions were administered intravenously via the tail vein or
orally gavaged. Blood samples of 150 µL were collected
via the jugular-vein cannula at 0 (immediately before
dosing), 2, 5 (iv only), 15 and 30 min and at 1, 2, 4, 6, 8,
12 and 24 hr after compound administration into EDTAcontaining tubes and kept on ice. Blood samples from rats
receiving no compounds were also collected for blanks
and calibration curves. Immediately after collecting the
blood sample, 150 µL of physiological saline (containing
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Figure 1. Chemical structure of (A) Niclosamide, (B) BPR1H366
and (C) BPR1H369.

30 units of heparin per mL) was injected to the rat via the
jugular-vein cannula. Plasma samples were then collected
by centrifugation (1500 ×g for 15 min at 4°C) with a Beckman Model AllegraTM 6R centrifuge and stored at –20°C
until LC-MS/MS analysis. The use of the animals was
approved by the institutional animal care and use committee of National Health Research Institutes.
III. Plasma Sample Preparation
Plasma (30 µL) was mixed with 60 µL of acetonitrile
containing 250 ng/mL of naproxen as the internal standard
(IS). The mixture was vortexed for 30 sec and then centrifuged at 21,000 ×g for 20 min in an Eppendorff centrifuge
Model 5417c at room temperature. An aliquot (10 µL) of
the supernatant was injected onto LC-MS/MS. To prepare
the samples of the calibration curve, the blank plasma (30
µL) containing various concentrations of niclosamide or
its analogs was mixed with 60 µL of acetonitrile containing the IS (250 ng/mL).
IV. LC-MS/MS Analysis
The HPLC system consisted of an Agilent 1100 series
LC System with two pumps (Palo Alto, CA, USA) and an
Xterra MS-C18 reverse-phase column (5 µm, 2.1 × 20 mm)
interfaced to an API 3000TM tandem mass spectrometer
equipped with a TurboIonSpray in the negative ion mode
(Applied Biosystems, Foster City, CA, USA). Mobile
phase consisted of 10 mM ammonium acetate containing
0.1% of formic acid (Solvent A) and acetonitrile (Solvent
B). The following stepwise gradient system was used:
70% A to 2% A (0-0.5 min), 2% A (0.5-4.0 min), 2% A to
70% A (4.0-4.5 min), 70% A (4.5-7.0 min). Total running
time was 7 min. The retention times of niclosamide,
BPR1H366, BPR1H369 and naproxen were 1.9, 2.1, 2.1
and 1.5 min, respectively. Data acquisition was via multiple reaction monitoring (MRN). The collision energy
was -40V for the analyte and -28V for IS. The ions monitored (m/z) for niclosamide, BPR1H366, BPR1H369 and
naproxen were 327.0/172.9, 315.9/280.1, 348.0/311.9 and
229.2/184.9, respectively. A good relationship observed
over the concentration range of 0.5-1000 ng/mL was fitted
using a quadratic regression mode and weighted by reciprocal concentration (1 / x) (r > 0.9983). The intra- and
inter-day accuracy ranged from 93 to 114% (n = 5). Intraand inter-day deviation of precision were all below 7%
(n = 5). The lower limit of quantitation (LLOQ) was 0.5
ng/mL. Plasma samples that had concentrations above
the upper limit of quantitation (1000 ng/mL) were diluted
proportionally with control plasma prior to extraction with
acetonitrile.
V. Data Analysis
Plasma concentration data were analyzed using
standard non-compartmental method with WinNonLin
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Table 1. Plasma concentrations of niclosamide, BPR1H366 and
BPR1H369 after a single 2-mg/kg intravenous dose to rats. (n = 3
per time point, mean ± SD)
Time

Concentration (ng/mL)
Niclosamide

BPR1H366

BPR1H369

2 min

8150 ± 1294

7783 ± 1531

5060 ± 707

5 min

3563 ± 1096

1620 ± 471

1703 ± 142

15 min

948 ± 306

280 ± 78

357 ± 64

30 min

205 ± 23

69.5 ± 32.6

111 ± 15

1 hr

56.6 ± 19.6

10.0 ± 3.5

23.3 ± 7.0

2 hr

38.3 ± 27.0

11.9 ± 13.4

12.1 ± 9.0

4 hr

11.2 ± 2.9

2.9 ± 1.0

6.0 ± 4.8

6 hr

6.8 ± 3.8

2.0 ± 0.4

3.3 ± 1.5

8 hr

6.3 ± 5.6

1.1 ± 0.4

2.0 ± 0.9

12 hr

2.4 ± 0.6

blq

1.0 ± 0.6

24 hr

blq

blq

blq

RESULTS AND DISCUSSION

blq: below the limit of quantitation (0.5 ng/mL)

Table 2. Plasma concentrations of niclosamide, BPR1H366 and
BPR1H369 after a single 5-mg/kg oral dose to rats. (n = 3 per time
point, mean ± SD)
Time

Concentration (ng/mL)
Niclosamide

BPR1H366

BPR1H369

15 min

340 ± 161

268 ± 146

98 ± 15

30 min

354 ± 152

107 ± 50

118 ± 19

1 hr

83.6 ± 31.7

31.6 ± 16.9

42.3 ± 18.6

2 hr

37.5 ± 10.6

71.1 ± 55.9

5.0 ± 3.1

4 hr

12.7 ± 11.9

22.4 ± 6.8

19.0 ± 5.2

6 hr

7.5 ± 3.5

14.4 ± 3.9

29.7 ± 8.6

8 hr

5.1 ± 2.9

9.3 ± 4.2

13.3 ± 2.4

12 hr

3.8 ± 2.0

3.2 ± 1.3

13.1 ± 8.9

24 hr

blq

blq

blq

software program from Pharsight Corp, (Mountain View,
CA, USA). The peak plasma concentration (C max) and
the time to reach Cmax (Tmax) were determined from the
actual data obtained after intravenous or oral administration. The terminal elimination rate constant (λ) was
calculated by fitting individual data for three or more
terminal points of the plasma concentration profile with
a log-linear regression equation using the least-squares
method. The corresponding elimination half-life (t1/2)
was calculated by dividing ln2 by λ. The area under the
plasma concentration-time curve from zero to infinity
(AUC0-inf ) was calculated using the trapezoidal rule with
extrapolation to infinity. The absolute bioavailability
(F, %) after oral administration was estimated as F(%) =
(AUCpo × Doseiv)/(AUCiv × Dose po) × 100.

blq: below the limit of quantitation (0.5 ng/mL)

Niclosamide is one of the halogenated salicylanilides,
which are highly hydrophobic having a very low aqueous
solubility(10). The aqueous solubility of its two analogs,
BPR1H366 and BPR1H369, is also low at 0.23 and 0.42
ng/mL, respectively. (in-house data). In this study, these
three compounds were dissolved in a mixture of DMSO/
cremophor EL/water (3/15/82 v/v/v) at a concentration of 2
mg/mL. These formulated true solutions stay physically
and chemically stable within 24 hr after preparation and
before dosing. The plasma concentrations of compounds
after single intravenous and oral administration in rats
were listed in Tables 1 and 2. Figures 2 and 3 illustrate
the plasma concentration verses time after the compounds
given intravenously and orally in rats, respectively. The
compounds in the rat plasma were measurable up to 12
hr after dosing for niclosamide (2.4 ± 0.6 ng/mL) and
BPR1H369 (1.0 ± 0.6 ng/mL), and 8 hr for BPR1H366 (1.1
± 0.4 ng/mL). Table 3 summarizes the pharmacokinetic
parameters of the three compounds in the two dosing
routes. The total body clearance (CL) of niclosamide,
BPR1H366 and BPR1H369 was 20.0 ± 2.9, 26.7 ± 4.4 and

Table 3. Pharmacokinetic parameters of niclosamide, BPR1H366 and BPR1H369 after a single 2-mg/kg intravenous and a 5-mg/kg oral
administration in rats.
t1/2

CL

Vss

Cmax

Tmax

AUC(0-inf.)

F

(mg/kg)

(hr)

2

6.7 ± 2.0

(mL/min/kg)

(L/kg)

(ng/mL)

(hr)

(ng/mL × hr)

(%)

20.0 ± 2.9

0.9 ± 0.4

-

-

1413 ± 118

-

i.v.

2

2.6 ± 0.3

26.7 ± 4.4

0.3 ± 0.1

-

-

1019 ± 203

-

BPR1H369

i.v.

2

3.7 ± 1.1

39.4 ± 6.7

1.1 ± 0.2

-

-

750 ± 113

-

Niclosamide
BPR1H366

p.o.

5

6.0 ± 0.8

-

-

354 ± 152

0.4 ± 0.1

429 ± 100

10

p.o.

5

2.9 ± 1.0

-

-

268 ± 146

0.3 ± 0.0

360 ± 66

12

BPR1H369

p.o.

5

3.3 ± 1.7

-

-

118 ± 18

0.4 ± 0.1

342 ± 71

15

Compound

Route

Niclosamide

i.v.

BPR1H366

Dose

CL: clearance; Vss: volume of distribution at steady state; t1/2: elimination half-life; AUC: area under the concentration-time curve; Cmax:
peak concentration; Tmax: time to reach Cmax; F: absolute bioavailability.
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39.4 ± 6.7 mL/kg/min, respectively, suggesting moderate clearance of these three compounds (11). The volume
of distribution at steady state (Vss) of niclosamide,
BPR1H366 and BPR1H369 was 0.9 ± 0.4, 0.3 ± 0.1 and 1.1
± 0.2 L/kg, respectively. The Vss of BPR1H366 was less
than the total body water in rats (~0.7 L/kg)(11), suggesting
that BPR1H366 was extracellularly distributed mainly in
the blood circulation. Niclosamide showed a longer t1/2
(6.7 ± 2.0 hr) than that of BPR1H366 (2.6 ± 0.3 hr) and
BPR1H369 (3.7 ± 1.1 hr). Niclosamide exhibited the highest AUC among the three compounds.
After an oral dose of 5-mg/kg, plasma concentration
of niclosamide, BPR1H366 and BPR1H369 was measurable up to 12 hr at 3.8 ± 2.0, 3.2 ± 1.3 and 13.1 ± 8.9 ng/
mL, respectively (Table 2). As shown in Figure 3, all three
compounds were rapidly absorbed with a Tmax less than 30
min after oral administration. Among them, niclosamide

Mean Plasma Concentration (ng/mL)

10000
Niclosamide
BPR1H366
BPR1H369

1000

100

10

1
0

2

4

6

8

10

12

Time Post-Dose (hr)

Figure 2. Plasma concentrations of niclosamide, BPR1H366 and
BPR1H369 after a single intravenous administration of 2-mg/kg to
rats (n = 3 per time point, mean ± SD).
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Figure 3. Plasma concentrations of niclosamide, BPR1H366 and
BPR1H369 after a single oral administration of 5-mg/kg to rats (n =
3 per time point, mean ± SD).

showed the highest Cmax at 354 ± 152 ng/mL, followed
by BPR1H366 at 268 ± 146 ng/mL, and BPR1H369 at 118
± 18 ng/mL. The concentration-time profiles revealed
a second peak at 2 hr for BPR1H366 and at 6 hr for
BPR1H369. Schaiquevich et al. proposed two mechanisms
for two peaks in a concentration-time profile: enterohepatic recirculation and the existence of multiple sites of
absorption along the gastrointestinal tract (12). Further
pharmacokinetic studies of these two compounds should
be performed to elucidate this phenomenon. Niclosamide
exhibited a higher AUC than the two analogs in both
intravenous and oral dosing routes, whereas the calculated
oral bioavailability of BPR1H369 was the highest among
the three showing a poor absorption at only 15%. The
oral bioavailability of niclosamide was 10%, which is in
agreement with the previously reported in humans (13).
In addition, an acute toxicology study reported an oral
LD 50 of niclosamide of > 5000 mg/kg in rats and the
no-observed adverse effect level of niclosamide was 2000
mg/kg/day of repeated daily oral administrations in a
4-week subacute toxicology study (10). These high toxicological doses demonstrated a good therapeutic index
and thus a large safety margin for niclosamide. All these
results, on the other hand, indicated a major fraction of the
orally administered niclosamide molecules retain within
the gastrointestinal tract and, therefore, better target the
parasites reside in the intestines as it has been an effective anthelmintics against the intestinal cestode infections
in humans and animals. Although niclosamide has been
used in humans for decades, very little of its pharmacokinetic data was reported in rats. Our results suggested that
the anti-SARS-CoV agent niclosamide and its two analogs
showed a low oral bioavailability in rats. Nonetheless, the
wide safety margin of niclosamide proves itself as a promising drug for treating SARS-CoV infections if a linearity
of pharmacokinetics observes within the dose range (5
to 2000 mg/kg, p.o.) reported. Whether the two analogs
exhibit the same pharmacokinetic properties in humans as
that in rats remains to be explored. Efforts on optimizing
formulations that increase oral absorption and on delivery
to the SARS-CoV-infected lungs of these compounds are
also warranted.
Porcine transmissible gastroenteritis virus (TGEV)
shares a similar 3-dimensional crystal protein structure
with SARS-CoV and has been utilized as a template in
silico study searching for SARS-CoV inhibitors(14-16). We
also found that niclosamide and the two analogs inhibited
the in vitro replication of TGEV in Swine Testis CRL-1763
cells (ST cells) with an IC50 for niclosamide, BPR1H366,
and BPR1H369 of 15, 3, and 2 μM, respectively (unpublished results). In addition to the activity against SARSCoV, the three compounds may also be used to treat
porcine TGEV infections. TGEV causes 65% of infectious
piglet diarrhea and results in high mortality in porcine
neonates in Taiwan (17-18). The cease of the SARS-CoV
pandemic in 2003 relieves the immediate pressure needed
to search for effective therapeutics for SARS-CoV infec-
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tions. Nevertheless, niclosamide against SARS-CoV and
TGEV as well as its two analogs against TGEV may be
reserved as a pool of backup active compounds for treating SARS-CoV infection in humans.

ACKNOWLEDGMENTS
We are grateful for the administrative supports from
Dr. Y.-S. Chao and Ranma Chen. This study was in part
supported by grants NSC 92-2751-B-400-008-Y and NSC
93-2751-B-400-004-Y from National Science Council,
Taiwan, ROC.

REFERENCES
1. Ksiazek, T. G., Erdman, D., Goldsmith, C., Zaki, S. R.,
Peret, T. and Emery, S. 2003. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl.
J. Med. 348: 1953-1966.
2. Drosten, C., Gunther, S., Preiser, W., van der Werf, S.,
Brodt, H. R., Becker, S., Rabenau, H., Panning, M.,
Kolesnikova, L., Fouchier, R. A., Berger, A., Burguiere,
A. M., Cinatl, J., Eickmann, M., Escriou, N., Grywna,
K., Kramme, S., Manuguerra, J. C., Muller, S., Rickerts,
V., Sturmer, M., Vieth, S., Klenk, H. D., Osterhaus, A.
D., Schmitz, H. and Doerr, H. W. 2003. Identification of
a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348: 1967-1976.
3. World Health Organization. 21 April 2004, posting date.
WHO [Online] http://www.who.int/csr/sars/country/
table2004_04_21/en/index.html.
4. Reynolds, J. E. F. 1989. In “Martindale: The Extra
Pharmacopoeia”. 29th ed. pp. 987-991. Reynolds, J. E.
F. ed., The Pharmaceutical Press, London, UK.
5. Katz, M. 1986. Anthelmintics. Current concepts in the
treatment of helminthic infections. Drugs 32(4): 358371.
6. G oldsmith, R. S. 1984. In “Basic and Clinical
Pharmacology” pp. 659-660: Katzung, B. G. ed. Lange
Medical, Los Angeles, U.S.A.
7. Lowe, D., Xi, J., Meng, X., Wu, Z., Qiu, D. and Spear,
R. 2005. Transport of Schistosoma japonicum cercariae
and the feasibility of niclosamide for cercariae control.
Parasitol. Int. 54(1): 83-89.

8. Wu, C. J., Jan, J. T., Chen, C. M., Hsieh, H. P., Hwang,
D. R., Liu, H. W., Liu, C. Y., Huang, H. W., Chen, S.
C., Hong, C. F., Lin, R. K., Chao, Y. S. and Hsu, T. A.
2004. Inhibition of severe acute respiratory syndrome
coronavirus replication by niclosamide. Antimicrob.
Agents Chemother. 48: 2693-2696.
9. Zhang, X. U. and Yap, Y. L. 2004. Old drugs as lead
compounds for a new disease? Binding analysis of
SARS coronavirus main proteinase with HIV, psychotic
and parasite drugs. Bioorg. Med. Chem. 12: 2517-2521.
10. World Health Organization. 2002. WHO [Online] http://
www.who.int/whopes/quality/en/Niclosamide.pdf.
11. Davies, B. and Morris, T. 1993. Physiological parameters in laboratory animals and humans. Pharm. Res.
10: 1093-1095.
12. Schaiquevich, P., Niselman, A. and Rubio, M. 2002.
Comparison of two compartmental models for describing ranitidine’s plasmatic profiles. Pharmacol. Res. 45:
399-405.
13. Campbell, W. C. and Rew, R. S. 1986. Chemotherapy of
parasitic disease, Pleum Press, New York, U.S.A.
14. Anand, K., Ziebuhr, J., Wadhwani, P., Mesters, J. R.
and Hilgenfeld, R. 2003. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS
drugs. Science 300(5626): 1763-1767.
15. Xiong, B., Gui, C. S., Xu, X. Y., Luo, C., Chen, J., Luo,
H. B., Chen, L. L., Li, G. W., Sun, T., Yu, C. Y., Yue,
L. D., Duan, W. H., Shen, J. K., Qin, L., Shi, T. L., Li,
Y. X., Chen, K. X., Luo, X. M., Shen, X., Shen, J. H.
and Jiang, H. L. 2003. A 3D model of SARS_CoV 3CL
proteinase and its inhibitors design by virtual screening.
Acta Pharmacol. Sin. 24(6): 497-504.
16. Jenwitheesuk E. and Samudrala, R. 2003. Identifying
inhibitors of the SARS coronavirus proteinase. Bioorg.
Med. Chem. Lett. 13(22): 3989-3892.
17. C hen, C. M., Pocock, D. H. and Britton, P. 1993.
Genomic organisation of a virulent Taiwanese strain of
transmissible gastroenteritis virus. Adv. Exp. Med. Biol.
42: 23-28.
18. C hen, C. M., Cavanagh, D. and Britton, P. 1995.
Cloning and sequencing of a 8.4-kb region from the 3’end of a Taiwanese virulent isolate of the coronavirus
transmissible gastroenteritis virus. Virus Res. 38(1):
83-89.
19. Swan, G. E. 1999. The pharmacology of halogenated
salicylanilides and their anthelmintic use in animals. J.
S. Afr. Vet. Ass. 70(2): 61-70.

